OVERVIEW

Cancer Summaries and Commentaries™: Report From Orlando on Advances in the Treatment of myeloproliferative neoplasms (MPNs) is organized by Physicians' Education Resource, LLC (PER).

Release Date: December 23, 2019
Expiration Date: December 23, 2020

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
This online activity is designed to update physicians on data presented at the 2019 American Society of Hematology Annual Meeting, held in December in Orlando, Florida. Cancer Summaries and Commentaries™: Report From Orlando on Advances in the Treatment of MPNs is an online continuing medical education (CME) activity that facilitates critical assessment and clinical integration of new clinical trial data. The activity reviews a selection of clinically relevant abstracts in myeloproliferative neoplasm presentations from the meeting. For each abstract, a short summary of key clinical data is accompanied by an expert perspective that provides insight into how clinicians can apply these findings to clinical practice to improve patient care.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Outline the design, efficacy, and safety of completed and ongoing clinical studies in patients with myeloproliferative neoplasms (MPNs)
• Explain findings from recently conducted trials that assessed emerging strategies for the treatment and management of MPNs
• Consider recent clinical trial data in the context of evolving treatment paradigms in the management of patients with MPNs

Benefits of Participating:
• Hear from the experts about recent clinical trials in the field of myeloproliferative neoplasms (MPNs) and their impact on clinical practice decision making
• Identify opportunities to implement emerging treatments for the management of MPNs including polycythemia vera, myelofibrosis, and essential thrombocythemia
• Explore the efficacy and safety outcomes from ongoing clinical trials in the treatment and management of MPNs